Therapeutic approaches for clostridium difficile infections

Current Protocols in Microbiology

Volumn , Issue SUPPL.30, 2013, Pages

  Marsh, Jane W ^a   Curry, Scott R ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antibiotics; Colitis; Diarrhea; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; FIDAXOMICIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; PLACEBO; PROTON PUMP INHIBITOR; RIFAXIMIN; TIGECYCLINE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; ANTITOXIN; BACTERIUM ANTIBODY; VACCINE;

AGE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOLYSIS; BACTERIOTHERAPY; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG COLON LEVEL; DRUG COST; DRUG TISSUE LEVEL; DRUG TREATMENT FAILURE; FECAL TRANSPLANTATION; FOOD AND DRUG ADMINISTRATION; HOST RESISTANCE; HUMAN; INHIBITION KINETICS; INTESTINE FLORA; LENGTH OF STAY; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RISK FACTOR; SPOROGENESIS; STOMACH ACID; TOXIN SYNTHESIS; UNITED STATES; CLOSTRIDIUM INFECTION; COLITIS; DIARRHEA; DRUG THERAPY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGY;

ANTIBIOTICS; COLITIS; DIARRHEA; VACCINE;

AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTITOXINS; BACTERIAL VACCINES; BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; DRUG THERAPY; HUMANS; IMMUNOTHERAPY; METRONIDAZOLE; VANCOMYCIN;

EID: 84891613410     PISSN: 19348525     EISSN: 19348533     Source Type: Journal    
DOI: 10.1002/9780471729259.mc09a03s30     Document Type: Article

References (63)

1. Babakhani, F., Gomez, A., Robert, N., and Sears, P. 2011. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob. Agents Chemother. 55:4427-4429.
2. Babakhani, F., Bouillaut, L., Gomez, A., Sears, P., Nguyen, L., and Sonenshein,A.L. 2012a. Fidaxomicin inhibits spore production in Clostridium difficile. Clin. Infect. Dis. 55:S162-S169.
3. Babakhani, F., Bouillaut, L., Sears, P., Sims, C., Gomez, A., and Sonenshein, A.L. 2012b. Fidaxomicin inhibits toxin production in Clostridium difficile. J. Antimicrob. Chemother. 68: 515-522.
4. Babcock, G.J., Broering, T.J., Hernandez, H.J., Mandell, R.B., Donahue, K., Boatright, N., Stack, A.M., Lowy, I., Graziano, R., Molrine, D., Ambrosino, D.M., and Thomas, W.D. Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-6347.
5. Belmares, J., Gerding, D.N., Parada, J.P., Miskevics, S.,Weaver, F., and Johnson, S. 2007. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J. Infect. 55:495-501.
6. Borriello, S.P. and Barclay, F.E. 1985. Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with nonpathogenic strains. J. Med. Microbiol. 19:339-350.
7. CDC. 2005. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb. Mortal. Wkly. Rep. 54:1201-1205.
8. CDC. 2008. Surveillance for communityassociated Clostridium difficile-Connecticut, 2006. MMWR Morb. Mortal. Wkly. Rep. 57:340-343.
9. Chang, J.Y., Antonopoulos, D.A., Kalra, A., Tonelli, A., Khalife, W.T., Schmidt, T.M., and Young, V.B. 2008. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197:435-438.
10. Clabots, C.R., Johnson, S., Olson, M.M., Peterson, L.R., and Gerding, D.N. 1992. Acquisition of Clostridium difficile by hospitalized patients: Evidence for colonized new admissions as a source of infection. J. Infect. Dis. 166:561-567.
11. Cornely, O.A., Crook, D.W., Esposito, R., Poirier, A., Somero, M.S., Weiss, K., Sears, P., Gorbach, S., and OPT-80-004 Clinical Study Group. 2012a. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A doubleblind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 12:281-289.
12. Cornely, O.A., Miller, M.A., Louie, T.J., Crook, D.W., and Gorbach, S.L. 2012b. Treatment of first recurrence of Clostridium difficile infection: Fidaxomicin versus vancomycin. Clin. Infect. Dis. 55:S154-S161.
13. Credito, K.L. and Appelbaum, P.C. 2004. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 48:4430-4434.
14. Crook, D.W., Walker, A.S., Kean, Y., Weiss, K., Cornely, O.A., Miller, M.A., Esposito, R., Louie, T.J., Stoesser, N.E., Young, B.C., Angus, B.J., Gorbach, S.L., Peto, T.E., and Study 003/004 Teams. 2012. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin. Infect. Dis. 55:S93-S103.
15. Curry, S.R., Marsh, J.W., Shutt, K.A., Muto, C.A., O'Leary, M.M., Saul, M.I., Pasculle, A.W., and Harrison, L.H. 2009. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin. Infect. Dis. 48:425-429.
16. Davies, A.H., Roberts, A.K., Shone, C.C., and Acharya, K.R. 2011. Super toxins from a super bug: Structure and function of Clostridium difficile toxins. Biochem. J. 436:517-526.
17. Debast, S.B., van Leengoed, L.A., Goorhuis, A., Harmanus, C., Kuijper, E.J., and Bergwerff, A.A. 2009. Clostridium difficile PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environ. Microbiol. 11:505-511.
18. Dumyati, G., Stevens, V., Hannett, G.E., Thompson, A.D., Long, C., Maccannell, D., and Limbago, B. 2012. Community-associated Clostridium difficile infections, Monroe County, New York, USA. Emerg. Infect. Dis. 18:392-400.
19. Edwards, D.I., Thompson, E.J., Tomusange, J., and Shanson, D. 1979. Inactivation of metronidazole by aerobic organisms. J. Antimicrob. Chemother. 5:315-316.
20. Figueroa, I., Johnson, S., Sambol, S.P., Goldstein, E.J., Citron, D.M., and Gerding, D.N. 2012. Relapse versus reinfection: Recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin. Infect. Dis. 55:S104-S109.
21. Freter,R. 1955. The fatal enteric cholera infection in the guinea pig, achieved by inhibition of normal enteric flora. J. Infect. Dis. 97:57-65.
22. Garey, K.W., Jiang, Z.D., Bellard, A., and Dupont, H.L. 2009. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: An uncontrolled pilot study. J. Clin. Gastroenterol. 43:91-93.
23. Garey, K.W., Ghantoji, S.S., Shah, D.N., Habib, M., Arora, V., Jiang, Z.D., and DuPont, H.L. 2011. A randomized, double-blind, placebocontrolled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J. Antimicrob. Chemother. 66:2850-2855.
24. Giannasca, P.J., Zhang, Z.X., Lei, W.D., Boden, J.A., Giel, M.A., Monath, T.P., and Thomas, W.D. Jr. 1999. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect. Immun. 67:527-538.
25. Gough, E., Shaikh, H., and Manges, A.R. 2011. Systematic reviewof intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 53:994-1002.
26. Greenberg, R.N., Marbury, T.C., Foglia, G., and Warny, M. 2012. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 30:2245-2249.
27. He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D.J.,Martin,M.J., Connor, T.R., Harris, S.R., Fairley, D., Bamford, K.B., D'Arc, S., Brazier, J., Brown, D., Coia, J.E., Douce, G., Gerding, D., Kim, H.J., Koh, T.H., Kato, H., Senoh, M., Louie, T., Michell, S., Butt, E., Peacock, S.J., Brown, N.M., Riley, T., Songer, G., Wilcox, M., Pirmohamed, M., Kuijper, E., Hawkey, P., Wren, B.W., Dougan, G., Parkhill, J., and Lawley, T.D. 2012. Emergence and global spread of epidemic healthcareassociated Clostridium difficile. Nat. Genet. 45:109-113.
28. Hirshon, J.M., Thompson, A.D., Limbago, B., McDonald, L.C., Bonkosky, M., Heimer, R., Meek, J., Mai,V., and Braden,C. 2011. Clostridium difficile infection in outpatients, Maryland and Connecticut, USA, 2002-2007. Emerg. Infect. Dis. 17:1946-1949.
29. Jhung, M.A., Thompson, A.D., Killgore, G.E., Zukowski, W.E., Songer, G., Warny, M., Johnson, S., Gerding, D.N., McDonald, L.C., and Limbago, B.M. 2008. Toxinotype V Clostridium difficile in humans and food animals. Emerg. Infect. Dis. 14:1039-1045.
30. Jiang, Z.D., Ke, S., Palazzini, E., Riopel, L., and Dupont, H. 2000. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob. Agents Chemother. 44:2205-2206.
31. Johnson, S., Schriever, C., Galang, M., Kelly, C.P., and Gerding, D.N. 2007. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 44:846-848.
32. Johnson, S., Schriever, C., Patel, U., Patel, T., Hecht, D.W., and Gerding, D.N. 2009. Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 15:290-291.
33. Khoruts, A., Dicksved, J., Jansson, J.K., and Sadowsky, M.J. 2010. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J. Clin. Gastroenterol. 44:354-360.
34. Kim, P.H., Iaconis, J.P., and Rolfe, R.D. 1987. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 55:2984-2992.
35. Kyne, L., Warny, M., Qamar, A., and Kelly, C.P. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397.
36. Kyne, L., Warny, M., Qamar, A., and Kelly, C.P. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-193.
37. Larson, K.C., Belliveau, P.P., and Spooner, L.M. 2011. Tigecycline for the treatment of severe Clostridium difficile infection. Ann. Pharmacother. 45: 1005-1010.
38. Louie, T.J., Miller, M.A., Mullane, K.M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., Shue, Y.K., and OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
39. Lowy, I., Molrine, D.C., Leav, B.A., Blair, B.M., Baxter, R., Gerding, D.N., Nichol, G., Thomas, W.D. Jr., Leney, M., Sloan, S., Hay, C.A., and Ambrosino, D.M. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205.
40. Manges, A.R., Labbe, A., Loo, V.G., Atherton, J.K., Behr, M.A., Masson, L., Tellis, P.A., and Brousseau, R. 2010. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficileassociated disease. J. Infect. Dis. 202:1877-1884.
41. Marsh, J.W., Arora, R., Schlackman, J.L., Shutt, K.A., Curry, S.R., and Harrison, L.H. 2012. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J. Clin. Microbiol. 50:4078-4082.
42. McFarland, L.V., Mulligan, M.E., Kwok, R.Y., and Stamm, W.E. 1989. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320:204-210.
43. Musher, D.M., Aslam, S., Logan, N., Nallacheru, S., Bhaila, I., Borchert, F., and Hamill, R.J. 2005. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis. 40:1586-1590.
44. Muto,C.A., Blank, M.K.,Marsh, J.W.,Vergis, E.N., O'Leary, M.M., Shutt, K.A., Pasculle, A.W., Pokrywka,M., Garcia, J.G., Posey, K., Roberts, T.L., Potoski,B.A., Blank, G.E., Simmons,R.L., Veldkamp, P., Harrison, L.H., and Paterson, D.L. 2007. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin. Infect. Dis. 45:1266-1273.
45. Nair, S., Yadav, D., Corpuz, M., and Pitchumoni, C.S. 1998. Clostridium difficile colitis: Factors influencing treatment failure and relapse-a prospective evaluation. Am. J. Gastroenterol. 93:1873-1876.
46. Noren, T., Akerlund, T., Back, E., Sjoberg, L., Persson, I., Alriksson, I., and Burman, L.G. 2004. Molecular epidemiology of hospitalassociated and community-acquired Clostridium difficile infection in a Swedish county. J. Clin. Microbiol. 42:3635-3643.
47. O'Connor, J.R., Galang, M.A., Sambol, S.P., Hecht, D.W., Vedantam, G., Gerding, D.N., and Johnson, S. 2008. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 52: 2813-2817.
48. Olson, M.M., Shanholtzer, C.J., Lee, J.T. Jr., and Gerding, D.N. 1994. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at theMinneapolisVAMedical Center, 1982-1991. Infect. Control Hosp. Epidemiol. 15:371-381.
49. Peláez, T., Cercenado, E., Alcalá, L., Marín, M., Martín-López, A., Martínez-Alarcón, J., Catalán, P., Sánchez-Somolinos,M., and Bouza, E. 2008. Metronidazole resistance in Clostridium difficile is heterogeneous. J. Clin.Microbiol. 46:3028-3032.
50. Pepin, J., Valiquette, L., and Cossette, B. 2005. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173:1037-1042.
51. Permpoonpattana, P., Hong, H.A., Phetcharaburanin, J., Huang, J.M., Cook, J., Fairweather, N.F., and Cutting, S.M. 2011. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect. Immun. 79:2295-2302.
52. Sambol, S.P., Merrigan, M.M., Tang, J.K., Johnson, S., and Gerding, D.N. 2002. Colonization for the prevention of Clostridium difficile disease in hamsters. J. Infect. Dis. 186:1781-1789.
53. Smith,D.G. and Robinson, H.J. 1945. The influence of streptomycin and streptothricin on the intestinal flora of mice. J. Bacteriol. 50:613-621.
54. Sougioultzis, S., Kyne, L., Drudy, D., Keates, S., Maroo, S., Pothoulakis, C., Giannasca, P.J., Lee, C.K., Warny, M., Monath, T.P., and Kelly, C.P. 2005. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128:764-770.
55. Teasley, D.G., Gerding, D.N., Olson, M.M., Peterson, L.R., Gebhard, R.L., Schwartz, M.J., and Lee, J.T. Jr. 1983. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 2:1043-1046.
56. Tian, J.H., Fuhrmann, S.R., Kluepfel-Stahl, S., Carman, R.J., Ellingsworth, L., and Flyer, D.C. 2012. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 30:4249-4258.
57. Vardakas, K.Z., Polyzos, K.A., Patouni, K., Rafailidis, P.I., Samonis, G., and Falagas, M.E. 2012. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: A systematic review of the evidence. Int. J. Antimicrob. Agents 40:1-8.
58. Villano, S.A., Seiberling, M., Tatarowicz, W., Monnot-Chase, E., and Gerding, D.N. 2012. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob. Agents Chemother. 56:5224-5229.
59. Voth, D.E. and Ballard, J.D. 2005. Clostridium difficile toxins: Mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-263.
60. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., and McDonald, L.C. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084.
61. Wenisch, C., Parschalk, B., Hasenhundl, M., Hirschl, A.M., and Graninger, W. 1996. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 22:813-818.
62. Wilson, K.H. and Sheagren, J.N. 1983. Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J. Infect. Dis. 147: 733-736.
63. Zar, F.A., Bakkanagari, S.R., Moorthi, K.M., and Davis, M.B. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45: 302-307.